A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
SirenWired
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

#SocPharm Tweetchat Transcript 1/11/2012

Posted by | 10:27pm on Wednesday, January 11, 2012

:
Welcome to the #socpharm chat! mark Bard is our guest moderator tonight. say hello!

:
We’ll assume your opinions are your own and do not reflect your employer #socpharm

:
Are you ready @: ? #socpharm

:
Having a slow start to #socpharm trying to log on computer for topics but get #bluescreenofdeath !

:
sorry about that #socpharm – some connectivity issues this evening – welcome

:
Hi everyone. Ciaran here – as always looking forward to a great hour of #socpharm

:
Hi All – Looking forward to the conversation – Chuck #SocPharm

:
@: me too – tx goodness for iphones #socpharm

:
@: I threw out a topic – does a FB post always deserve brand response? #socpharm

:
great q @: – I believe this goes back to the level of customer service integration at the company and brand level #socpharm

:
@: Stats show a valid expectation for a response to a question. It’s a basic form of showing respect, right? #SocPharm

:
I think if someone takes the time to ask a brand a legit question the brand should respond. Common courtesy #socpharm

:
if we include corporate as a brand response and it’s a corporate FB page – sure, the company has an obligation to respond to q’s #socpharm

:
100% agreed – but at this point – a public brand conversation seems a no go for most #socpharm

:
we live in a world near term of …. call the #800 #socpharm

:
T1: IMO it’s similar to responding to a phone call complaint. Triage and if big enough issue, bigger response. #socpharm

:
I think we agree it’s pretty important & from what I can tell Pharma is trying to do that (whether w/canned or unique replies) #socpharm

:
another q – T2 – comments on the news this week that webmd forecasts a down year (due to pharma) and a tough yr ahead? #socpharm

:
is this indicative of the space in 2012 or this company specific? #socpharm

:
@: are u following #socpharm? Other comments there…

:
T2: I think it’s space for 2012. Mergers of companies=mergers of budgets #socpharm

:
i am @: – but still seems slow #socpharm

:
IMHO always found WebMD to be overpriced… Perhaps bubble burst? #socpharm

:
@: please expand #socpharm

:
@: ok – so are we seeing a reallocation into other portals and into emerging communities? #socpharm

:
@: One source on quick search shows projected moderate growth of pharma overall at about 3%. #socpharm

:
Plus FB ads now offer very targeted alternative to WebMD and you only pay when someone clicks #socpharm

:
great point @: – they cited “social networks” as threat – anyone else see FB taking share from traditional health? #socpharm

:
ie #HBA in the Philly had sponsors at Wyeth, Cephalon. Now with mergers, harder to get funds from 1 comp= 3 cos. Same w agencies #socpharm

:
@: possibly, $ is going into online listening, communities, FB & YouTube so probably coming from other things #socpharm

:
I agree RT @: : @: $ is going into online listening, communities, FB & YouTube so coming from other things #socpharm

:
@: among listening, community, fb, yt – where does this group see the most interest in 2012? #socpharm

:
and if you say FB – please explain #socpharm

:
where is innovation specific to FB for brands in 2012? assuming pharma response remains “call the 800#” as you browse the FB site #socpharm

:
@: Great opp for pharma in listening to learn unmet needs/lingo and YT for content – user-friendly & less risk #socpharm

:
final one on this theme – if social is changing spend – is G+ in the mix in 2012? #socpharm

:
I like YouTube-video is powerful medium as your previous company @ showed! Popular globally & can turn off comments #socpharm

:
@: value of G+ is TBD #socpharm

:
and given recent fda insight – is twitter relevant in 2012? #socpharm

:
@: gr8 question re Google+ Search colleague is very keen to get us to try to start using! #socpharm

:
Frieda Hernandez here from Siren joining #socpharm

:
and … any thoughts on the recent decision (and response) to integrate G+ into search? #socpharm

:
Twitter should only be relevant if your target audience is there. In most cases no. #socpharm

:
@: BSOD on MacOS? Hold down Shift on Restart to boot in Safe mode (after #socpharm)

:
@: nice G+ forecast @: included http://t.co/vHcCi1b9 #socpharm

:
For those not familiar, here’s Google news http://t.co/m6qc7KRU #socpharm

:
@: so the FB budget shift ahead is all about scale – or is it something else? #socpharm

:
RT @: : @: I haven’t heard a single client mention G+. Not on their radar as far as I can tell #socpharm

:
@: q was related to comment that G+ is TBD#socpharm

:
anyone want to disagree with @: … is twitter relevant to pharma? ever? #socpharm

:
@: more budget allocated to what’s currently working – more reliable ROI. #socpharm

:
@: LOL I don’t think that’s what I tweeted exactly, but I like the way you are stirring up the pot! #socpharm

:
twitter and social listening Q – seems a lot of spam within twitter specific to pharma – any data mining value? examples? #socpharm

:
digitalhealthco: Twitter is another tool for microtargeting which most pharma is not doing. We see value in #raredisease #socpharm

:
And back to WebMD – there’s a finite limit to the number of sponsored cholesterol & allergy sections they can sell :) #socpharm

:
@: – I try – seems like a calm crowd tonight #socpharm

:
@: ok – so it has relevance to targeted efforts to find, engage, and drive to your programs? #socpharm

:
@: do u want to take the last few minutes & share upcoming plans for Digital Health Coalition? #socpharm

:
@: ok, so we’re not finding new people for awareness – does that mean portals must reinvent with #socpharm – can they?

:
@: sure – thanks #socpharm

:
Correct. #Raredisease patients use hashtags too.#socpharm

:
as always, http://t.co/jC9F8B6c to learn more and request info #socpharm

:
for DHC members (and peers within firms) we are hosting an event Feb 6 in NYC from 2-5pm – Social Guiding Principles Summit #socpharm

:
@: that’s a great question, I’m going to raise again at another chat! #socpharm

:
we have a short list of principles we have been refining with our 70+ member organizations #socpharm

:
we plan to discuss and outline plans for 2012 – hear from thought leaders including sanofi, gilead, facebook, palio and others #socpharm

:
@: looking forward to meeting other DHC members & talking on Feb 6 #socpharm

:
@: Sounds like a great line-up. #socpharm

:
@: and we look forward to seeing you there – a key goal is to continue to build consensus on the core issues for social #socpharm

:
Big thanks @: (Mark Bard) for moderating tonight. Next week @ will be posing the questions at #socpharm

:
@: thanks – we need more information sharing in this industry #socpharm

:
well thanks everyone for the engagement this evening – shout out to the siren team for keeping it going #socpharm

:
RT @: : @: thanks – we need more information sharing in this industry #socpharm

:
Nice chatting – Thanks #socpharm

:
@: Thank you for some very thought-provoking questions and thanks to @: too #socpharm

:
@: Look forward to the party ;) #socpharm

About Eileen O'Brien

Eileen has more than 16 years of digital healthcare marketing experience. She is an opinion leader on social media and biopharma, and has been invited to speak at industry conferences and quoted in publications.

View other posts from Eileen

3 Pingbacks/Trackbacks

    14 January 2012 at 1:01am
    Transcript from last #socpharm chat ...
  • Eileen O'Brien
  • 14 January 2012 at 3:01am
    Transcript from last #socpharm chat ...
  • jimlefevere
  • 16 January 2012 at 3:01pm
    RT @EileenOBrien: Transcript from ...
  • Dana Webster
Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com